Capricor Therapeutics, Inc.

NasdaqCM:CAPR Stock Report

Market Cap: US$200.3m

Capricor Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Capricor Therapeutics has a total shareholder equity of $22.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $58.7M and $36.1M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$39.49m
EquityUS$22.60m
Total liabilitiesUS$36.13m
Total assetsUS$58.73m

Recent financial health updates

Recent updates

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Feb 01
Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Oct 14
We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result

Sep 25

Capricor Therapeutics slumps 9% on $75M stock offering

Jun 21

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

May 16
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Mar 13
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Capricor signs intellectual property license for COVID-19 serology test platform

Feb 01

Capricor and Lonza tie up in DMD development

Jan 12

Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19

Nov 24

Financial Position Analysis

Short Term Liabilities: CAPR's short term assets ($50.9M) exceed its short term liabilities ($31.3M).

Long Term Liabilities: CAPR's short term assets ($50.9M) exceed its long term liabilities ($4.9M).


Debt to Equity History and Analysis

Debt Level: CAPR is debt free.

Reducing Debt: CAPR had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CAPR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CAPR has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 1.6% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.